Overview

Donafenib Combined With Hepatic Artery Chemoembolization for Perioperative Treatment of Liver Transplantation

Status:
Not yet recruiting

Trial end date:
2025-10-15

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety and efficacy of the combination of donafenib and TACE in the perioperative period of liver transplantation.

Phase:

Phase 2

Details

Lead Sponsor:

Beijing Tsinghua Chang Gung Hospital

Collaborator:

Suzhou Zelgen Biopharmaceuticals Co.,Ltd